{
  "ticker": "LLY",
  "target_date": "2024-12-16",
  "actual_date": "2024-12-16",
  "collected_at": "2025-12-08T11:09:14.761902",
  "price": {
    "open": 786.14,
    "high": 793.86,
    "low": 769.51,
    "close": 773.2325439453125,
    "volume": 3426200,
    "change_1d_pct": -1.28,
    "change_7d_pct": -5.65,
    "change_30d_pct": -4.72
  },
  "technicals": {
    "rsi_14": 58.35,
    "sma_20": 778.25,
    "sma_50": 826.21,
    "macd": -7.244,
    "macd_signal": -8.898,
    "macd_histogram": 1.654,
    "bb_upper": 839.64,
    "bb_lower": 716.86,
    "price_vs_sma20_pct": -0.64,
    "price_vs_sma50_pct": -6.41,
    "volume_ratio": 0.86
  },
  "fundamentals": {
    "market_cap": 891373879296,
    "pe_ratio": 48.717785,
    "forward_pe": 43.880405,
    "price_to_book": 37.437126,
    "price_to_sales": 15.001294,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.58,
    "pct_from_52w_low": 59.4
  },
  "macro": {
    "spy": {
      "price": 599.5,
      "change_1d_pct": 0.43,
      "change_7d_pct": -0.17
    },
    "vix": {
      "level": 14.69,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.4
    },
    "dollar_index": {
      "level": 106.86
    },
    "gold": {
      "price": 2651.4
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Novo\u2019s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.",
      "source": "Yahoo",
      "datetime": 1734386580,
      "summary": "Catalent says it worked on more than half of the new drugs approved by the FDA over the past 10 years.",
      "url": "https://finnhub.io/api/news?id=6e41469b058b9c11b165af6146853312a5b25708747e4f88669c4997b6b4886f"
    },
    {
      "headline": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
      "source": "MarketWatch",
      "datetime": 1734366780,
      "summary": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=2e8a56d768e98e8581c45eab791ce714e7bdaf193453ac89b9f4051dae45c6cc"
    },
    {
      "headline": "Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs.",
      "source": "MarketWatch",
      "datetime": 1734358920,
      "summary": "Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs.",
      "url": "https://finnhub.io/api/news?id=f41e72a950ed1b2dd59a424074df6b51376a2e758cb040196c242cef41aab89b"
    },
    {
      "headline": "Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?",
      "source": "Yahoo",
      "datetime": 1734354059,
      "summary": "The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others are coming.",
      "url": "https://finnhub.io/api/news?id=6cb607d103415376d9d07c90278dcd33f958e24cf9dd571a2bc12ffbc7065c56"
    },
    {
      "headline": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
      "source": "Yahoo",
      "datetime": 1734351780,
      "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
      "url": "https://finnhub.io/api/news?id=521b4a3c62765effaf186c598570ecb2b51c468ba4416fff3cee3a4eba952d87"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-11-20",
      "description": "xslF345X05/wk-form4_1732138184.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000278/xslF345X05/wk-form4_1732138184.xml"
    },
    {
      "form": "4",
      "date": "2024-11-20",
      "description": "xslF345X05/wk-form4_1732138122.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000276/xslF345X05/wk-form4_1732138122.xml"
    },
    {
      "form": "4",
      "date": "2024-11-20",
      "description": "xslF345X05/wk-form4_1732138066.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000274/xslF345X05/wk-form4_1732138066.xml"
    },
    {
      "form": "4",
      "date": "2024-11-20",
      "description": "xslF345X05/wk-form4_1732138010.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000272/xslF345X05/wk-form4_1732138010.xml"
    },
    {
      "form": "4",
      "date": "2024-11-20",
      "description": "xslF345X05/wk-form4_1732137954.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000270/xslF345X05/wk-form4_1732137954.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}